The validation of estrogen receptor 1 mRNA expression as a predictor of outcome in patients with metastatic non-small cell lung cancer-Reference-Cited by-同舟云学术

The validation of estrogen receptor 1 mRNA expression as a predictor of outcome in patients with metastatic non-small cell lung cancer

Published:2013-11-14 Issue:10 Volume:134 Page:2314-2321
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Atmaca Akin¹,Al-Batran Salah-Eddin²,Wirtz Ralph Markus³⁴,Werner Dominique²,Zirlik Sabine⁵,Wiest Gunther⁶,Eschbach Corinna⁷,Claas Silke³⁴,Hartmann Arndt³,Ficker Joachim Hans⁸,Jäger Elke¹,Brueckl Wolfgang Michael⁸

Affiliation:

1. Department of Hematology and Oncology; Krankenhaus Nordwest; Frankfurt am Main Germany

2. Institute of Clinical Cancer Research (IKF) Kankenhaus Nordwest; UCT-University Cancer Center; Frankfurt am Main Germany

3. Department of Pathology; Friedrich-Alexander-University Erlangen-Nuremberg; Erlangen Germany

4. STRATIFYER Molecular Pathology GmbH; Cologne Germany

5. Department of Internal Medicine 1; Friedrich-Alexander-University Erlangen-Nuremberg; Erlangen Germany

6. Department of Pneumology; Asklepios Hospital Harburg; Hamburg Germany

7. Department of Thoracic Oncology; University Heidelberg; Heidelberg Germany

8. Department of Internal Medicine 3; Klinikum Nuernberg; Nuremberg Germany

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference34 articles.

1. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

2. Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol,2012

3. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer;Kwak;N Engl J Med,2010

4. Lung cancer in women: analysis of the national Surveillance. Epidemiology, and end results database;Fu;Chest,2005

5. Hormone replacement therapy is associated with decreased survival in women with lung cancer;Ganti;J Clin Oncol,2006

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular In Vitro and In Vivo Diagnostics as the Impartible Basis of Multimodal Therapy Approaches in Precision Oncology;Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum;2024

2. Phytochemicals as estrogen receptor modulators?—a commentary of a network pharmacology study of two commonly employed Chinese herbal medicines in non-small cell lung cancer treatment;Translational Cancer Research;2023-12

3. The Comprehensive Analysis of N6-Methyadenosine Writer METTL3 and METTL14 in Gastric Cancer;Journal of Oncology;2023-02-21

4. Identification of molecular mechanism of the anti-lung cancer effect of Jin Ning Fang using network pharmacology and its experimental verification;All Life;2022-06-23

5. High expression of ERBB2 is an independent risk factor for reduced recurrence-free survival in patients with stage T1 non-muscle-invasive bladder cancer;Urologic Oncology: Seminars and Original Investigations;2022-02